HitGen Inc. (SHA:688222)
China · Delayed Price · Currency is CNY 44.69
+1.01 (2.31%)
At close: Sep 30, 2026
HitGen Revenue
HitGen had revenue of 185.44M CNY in the quarter ending June 30, 2026, with 54.18% growth. This brings the company's revenue in the last twelve months to 644.54M, up 40.34% year-over-year. In the year 2025, HitGen had annual revenue of 525.57M with 23.09% growth.
Revenue (ttm)
644.54M
Revenue Growth
+40.34%
P/S Ratio
27.78
Revenue / Employee
912.94K
Employees
706
Market Cap
17.91B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 525.57M | 98.58M | 23.09% |
| Dec 31, 2024 | 426.99M | 55.66M | 14.99% |
| Dec 31, 2023 | 371.32M | 41.67M | 12.64% |
| Dec 31, 2022 | 329.65M | 18.59M | 5.98% |
| Dec 31, 2021 | 311.06M | 67.46M | 27.69% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Yili Chuanning Biotechnology | 4.37B |
| Xiamen Amoytop Biotech | 4.02B |
| Anhui Anke Biotechnology (Group) | 2.45B |
| Nanjing Vazyme Biotech | 1.47B |
| Shanghai Medicilon | 1.38B |
| BrightGene Bio-Medical Technology | 1.36B |
| Sinocelltech Group | 1.25B |
| Evopoint Biosciences | 1.11B |